NeuroMetrix Reports Q2 2022 Financial Results
WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the...
News
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience,...
Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma
--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and...
Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results
CARLSBAD, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management...
Teleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings
The company aims to raise awareness and education about BPH, a common men’s health conditionWAYNE, Pa., July 21, 2022 (GLOBE...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023
Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in...
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
July 21, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives...
Addex Completes Reduction in Nominal Value of Shares
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
Addex Provides Corporate Update and Financial Guidance
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
Virax Biolabs Group Limited Announces Pricing of $6.75 Million Initial Public Offering
London, United Kingdom, July 20, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an...
Sotera Health Announces Second-Quarter 2022 Earnings Release Date
Names Michael F. Biehl as Interim Chief Financial OfficerCLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC),...
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will...
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
PointCross Releases eDataValidator for SDTM, ADaM, SEND, and Define.XML Conformance to Prevailing FDA, CDISC, and PMDA Rules
Integrated QC dashboard and unlimited validation cycles for interim and final datasets creates industry's most user-friendly validator PointCross Logo PointCross...
FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA)...